Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beryl Drugs Ltd has submitted three compliance documents to BSE for the quarter ended 31 March 2026, as required under SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. The filings include a Regulation 74(5) certificate under SEBI (Depositories and Participants) Regulations, 2018, a Regulation 7(3) compliance certificate confirming maintenance of physical and electronic share transfer facilities, and a Regulation 57(5) non-applicability certificate. The company's Registrar and Share Transfer Agent, Adroit Corporate Services Private Limited (SEBI Registration: INR000002227), has certified that both physical and electronic share transfer activities were maintained throughout the period from 1 April 2025 to 31 March 2026. The filing is signed by Mr. Sandeep Shinde, Director/Compliance Officer/Company Secretary.
This is a routine regulatory compliance filing with no material impact on business operations or shareholder value. It simply confirms that the company has met its ongoing listing and depository compliance requirements for the quarter.